The research team headed by Prof. Dr. Kandioler is convinced that the p53 gene can be applied as a global indicator for the efficacy of chemotherapeutic substances and radiotherapy. Why are we so certain of this? Because the data from our clinical studies consistently demonstrates a powerful interaction between the p53 gene and many cancer therapies.
Worldwide, we are the first to outline this interaction. On account of the global importance for cancer therapy, the p53 gene is the first biomarker to be tested in a specially developed prospective, randomized interaction study.
Details about our clinical marker studies can be found on our website under: www.p53.at.